Medium NAPLEX Heart Failure Practice Questions

Concept Explanation

Heart failure is a clinical syndrome characterized by the heart's inability to pump sufficient blood to meet the body's metabolic demands, often classified by ejection fraction into Heart Failure with reduced Ejection Fraction (HFrEF) and Heart Failure with preserved Ejection Fraction (HFpEF). For the NAPLEX, understanding the pharmacological management of HFrEF is paramount, specifically focusing on the "four pillars" of therapy: Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) or ACE inhibitors/ARBs, evidence-based beta-blockers, Mineralocorticoid Receptor Antagonists (MRAs), and Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors. These medications are proven to reduce mortality and hospitalizations. Clinicians must also manage fluid volume using loop diuretics and monitor for electrolyte imbalances, particularly potassium and magnesium levels. This NAPLEX Prep guide focuses on the clinical application of these guidelines to ensure patient safety and therapeutic efficacy.

Solved Examples

1. Calculating Loop Diuretic Equivalency: A patient is being transitioned from 40 mg of oral furosemide to oral torsemide. What is the equivalent dose of torsemide?
   1. Identify the standard equivalency ratio for loop diuretics: 40 mg Furosemide = 20 mg Torsemide = 1 mg Bumetanide.
   2. Apply the ratio to the current dose: $40 \text{ mg Furosemide} \times \frac{20 \text{ mg Torsemide}}{40 \text{ mg Furosemide}} = 20 \text{ mg Torsemide}$.
   3. Final Answer: 20 mg of oral torsemide.
2. Managing Hyperkalemia in MRA Therapy: A patient with HFrEF and an Ejection Fraction (EF) of 30% has a serum potassium of $5.2 \text{ mEq/L}$ and a SCr of $1.8 \text{ mg/dL}$. Should spironolactone be initiated?
   1. Review the initiation criteria for MRAs: Potassium should be $< 5.0 \text{ mEq/L}$ and CrCl should be $> 30 \text{ mL/min}$ (or SCr $< 2.5 \text{ mg/dL}$ in men, $< 2.0 \text{ mg/dL}$ in women).
   2. Compare the patient's labs: Potassium is $5.2 \text{ mEq/L}$, which exceeds the threshold.
   3. Conclusion: Spironolactone should not be initiated until potassium is corrected to below $5.0 \text{ mEq/L}$.
3. Transitioning to ARNI Therapy: A patient is currently taking lisinopril 20 mg daily and the physician wants to switch to Entresto (sacubitril/valsartan). What is the mandatory washout period?
   1. Recall the mechanism of ARNIs: Sacubitril inhibits neprilysin, which breaks down bradykinin. ACE inhibitors also increase bradykinin.
   2. Identify the risk: Combining or failing to space these drugs increases the risk of angioedema.
   3. Determine the timeframe: A 36-hour washout period is required when switching from an ACE inhibitor to an ARNI. (Note: This is not required when switching from an ARB).

Practice Questions

1. A 64-year-old male with HFrEF (EF 25%) presents with a heart rate of 82 bpm while on carvedilol 25 mg BID, lisinopril 40 mg daily, and spironolactone 25 mg daily. He is in normal sinus rhythm. Which medication should be considered next to specifically reduce the risk of hospitalization?

2. Which of the following beta-blockers is NOT indicated for the management of chronic heart failure with reduced ejection fraction based on clinical trial evidence?

3. A patient with HFrEF is started on Dapagliflozin 10 mg daily. What is the primary mechanism by which this medication provides benefit in heart failure, independent of glycemic control?

4. A patient with NYHA Class III heart failure and a history of angioedema from an ACE inhibitor requires further optimization of their regimen. Which combination is the best alternative for mortality benefit in this patient?

5. Calculate the equivalent dose of intravenous (IV) furosemide for a patient currently taking 80 mg of oral furosemide daily.

6. A patient is being initiated on digoxin for heart failure. What is the target therapeutic serum concentration range for digoxin in the context of heart failure?

7. A patient with HFrEF and a history of gout is started on a loop diuretic. What electrolyte monitoring is most critical to prevent an exacerbation of gout and maintain cardiac stability? (Review NAPLEX Renal Therapeutics for similar electrolyte concerns).

8. Which of the following is a common side effect of Ivabradine that patients should be counseled on?

9. When using the AI Question Generator to study heart failure, a student encounters a question about Verquvo (vericiguat). What is the mechanism of action for this medication?

10. A patient is currently taking Metoprolol Tartrate 50 mg BID for hypertension. They are recently diagnosed with HFrEF. What is the appropriate action regarding their beta-blocker therapy?

Answers & Explanations

1. Ivabradine: Ivabradine is indicated for patients with HFrEF (EF $\leq 35\%$) who are in sinus rhythm with a resting heart rate $\geq 70 \text{ bpm}$ despite being on maximally tolerated beta-blockers. It reduces the risk of hospitalization.
2. Metoprolol Tartrate: Only three beta-blockers are evidence-based for HFrEF: Bisoprolol, Carvedilol (IR and CR), and Metoprolol Succinate (Extended-Release). Metoprolol Tartrate has not shown the same mortality benefits in clinical trials.
3. Osmotic Diuresis and Natriuresis: SGLT2 inhibitors like Dapagliflozin reduce preload and afterload through osmotic diuresis and natriuresis. They also improve myocardial metabolism and reduce cardiac fibrosis, which are benefits seen even in non-diabetic patients.
4. Hydralazine and Isosorbide Dinitrate (BiDil): For patients who cannot tolerate ACEIs, ARBs, or ARNIs due to angioedema or renal impairment, the combination of hydralazine and isosorbide dinitrate is the preferred alternative for mortality benefit, especially in African American patients.
5. 40 mg IV: The oral to IV ratio for furosemide is 2:1. Therefore, 80 mg PO is equivalent to 40 mg IV. Note that for bumetanide and torsemide, the ratio is 1:1.
6. 0.5 - 0.9 ng/mL: In heart failure, lower serum concentrations of digoxin are targeted ($0.5 - 0.9 \text{ ng/mL}$) compared to atrial fibrillation ($0.8 - 2.0 \text{ ng/mL}$) to minimize toxicity while maintaining benefit.
7. Uric Acid and Potassium: Loop diuretics can increase uric acid levels, potentially triggering gout. They also cause hypokalemia, which can sensitize the heart to arrhythmias and increase digoxin toxicity risk.
8. Phosphenes: Ivabradine commonly causes phosphenes, which are transient enhanced visual brightness or "halos" in the visual field. This is due to its inhibition of $I_f$ channels in the retina.
9. Soluble Guanylate Cyclase (sGC) Stimulator: Vericiguat stimulates sGC, the receptor for nitric oxide, leading to increased levels of cGMP, which results in smooth muscle relaxation and vasodilation.
10. Switch to Metoprolol Succinate: Since the patient has HFrEF, they should be transitioned to an evidence-based beta-blocker. Metoprolol Tartrate should be switched to Metoprolol Succinate and titrated to the target dose of 200 mg daily.

For more practice with complex cardiovascular regimens, you might find our NAPLEX Anticoagulation Practice Questions helpful, as many heart failure patients also require stroke prevention for atrial fibrillation.

1. Which medication requires a 36-hour washout period when switching from Enalapril?

• ALosartan
• BSacubitril/Valsartan
• CSpironolactone
• DMetoprolol Succinate

Frequently Asked Questions

What are the four pillars of HFrEF therapy?

The four pillars of HFrEF therapy include an ARNI (preferred) or ACEI/ARB, an evidence-based beta-blocker (bisoprolol, carvedilol, or metoprolol succinate), a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor. These medications are initiated to reduce mortality, prevent hospitalizations, and improve quality of life.

Why is the 36-hour washout period necessary for ARNIs?

The washout period is required when switching from an ACE inhibitor to an ARNI to prevent the accumulation of bradykinin, which significantly increases the risk of life-threatening angioedema. This delay is not necessary when switching from an ARB to an ARNI because ARBs do not inhibit the breakdown of bradykinin.

Which beta-blockers are used in heart failure?

Only three specific beta-blockers have demonstrated a reduction in mortality for HFrEF: bisoprolol, carvedilol (Coreg), and metoprolol succinate (Toprol XL). Other beta-blockers, such as atenolol or metoprolol tartrate, do not have the same evidence base for heart failure management.

How do SGLT2 inhibitors help in heart failure?

SGLT2 inhibitors provide benefits in heart failure by promoting natriuresis and osmotic diuresis, which reduces cardiac preload and afterload. They also improve myocardial energetics and reduce cardiac remodeling, providing benefits regardless of whether the patient has diabetes.

What is the role of loop diuretics in heart failure?

Loop diuretics are primarily used for symptom management to reduce fluid congestion and achieve a "dry" weight. Unlike the four pillars of therapy, loop diuretics have not been shown to reduce mortality in heart failure patients but are essential for preventing hospitalizations due to fluid overload.